Clinical trials recruiting for Immunotherapy
40
Recruiting trials
10
US states with sites
10
Countries
0%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| Missouri | 2 |
| Arkansas | 1 |
| California | 1 |
| Illinois | 1 |
| Indiana | 1 |
| Maryland | 1 |
| New York | 1 |
| Oklahoma | 1 |
| Pennsylvania | 1 |
| Texas | 1 |
Top cities
St Louis, Missouri 2Chicago, Illinois 1Fort Smith, Arkansas 1Forth Worth, Texas 1Frederick, Maryland 1Indianapolis, Indiana 1Long Beach, California 1New York, New York 1Oklahoma City, Oklahoma 1Pittsburgh, Pennsylvania 1
Self-screener
Recruiting trials
- 68Ga-grazytracer PET Assists in Diagnosing Pseudoprogression Following Immunotherapy in Lung Cancer.
- A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in Locally Advanced Rectal Cancer
- A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer
- A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC
- Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients
- Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
- Association of Psychological Distress in Patients With Lung Cancer
- Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer
- Cadonilimab Combined With Stereotactic Radiotherapy as Second-line Treatment for Brain Metastases
- Camrelizumab Combined With Neoadjuvant Chemotherapy After Stent Placement for Left-Sided Obstructive Colonic Cancer
- Characterization of Multi-Omics Landscapes and AI Pathological Prediction Model for Long-Term Survival in NSCLC Immunotherapy
- Clinical Study of PSMA-targeted CAR-T Cells in the Treatment of Castration-resistant Prostate Cancer
- EXERCISE AND THE IMMUNE RESPONSE IN LUNG CANCER
- Efficacy of Neoadjuvant Immunotherapy in Patients With Lung Cancer
- Evaluating a Fasting-mimicking Diet in Combination With Immunotherapy in Patients With Non-small Cell Lung Cancer
- Exploration of the Dynamic Changes and Mechanisms of the Immune Microenvironment in Advanced Colorectal Cancer Treated With IBI363 Combination Therapy
- Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases
- GPC3-CAR-T Cells for Immunotherapy of Cancer With GPC3 Expression
- GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers
- Genomic and Methylation Markers in SCLC and LCNEC for Chemo-Immunotherapy Resistance Prediction (STRATUS)
- Investigating Real-Time Immunotherapy Symptoms Study
- Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer
- Molecular Monitoring of cfDNA by ddPCR in Non-small Cell Lung Cancer Treated by Immunotherapy.
- Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC
- Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer
- Omitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and Chemotherapy
- Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer
- Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK
- Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer
- Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA
- Predicting Response to Immunotherapy From Analysis of Live Tumor Biopsies (ELEPHAS-05)
- Primary Tumor Radiotherapy Omitting CTV for Patients With Advanced NSCLC Responded to Immunotherapy and Chemotherapy
- SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC
- Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial
- Stereotactic Radiotherapy Combined With Adebrelimab and TCb (Nab-paclitaxel + Carboplatin) in Neoadjuvant Treatment of TNBC
- Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung Cancer
- The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer
- The Real World Study of Neoadjuvant Immunotherapy in Early Stage NSCLC in China
- To Conduct Multi-omics Integrated Studies in Peripheral Blood, Such as Fragment Omics, Metabolomics and Epigenetics, and Establish Non-invasive Dynamic Follow-up Monitoring Programs During Perioperative and Postoperative Periods (Observational Study)
- VSV-02 Compassionate Use in Advanced Solid Tumors
Related conditions
Trials recruiting for Immunotherapy often also study these conditions. Each links to its own recruiting-trial list.
Lung cancer 2180Colorectal cancer 1359Radiotherapy 31Non-small cell lung cancer 507Neoadjuvant Therapy 23Chemotherapy 25Targeted Therapy 8Melanoma 487Breast cancer 2239Rectal cancer 152
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Immunotherapy trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.